Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
13 Jan 2021
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
Read More
9 Jan 2021
Disposals of own shares
Read More
18 Dec 2020
Disposals of own shares
Read More
4 Dec 2020
Disposals of own shares
Read More
20 Nov 2020
Disposals of own shares
Read More
17 Nov 2020
UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
Read More
12 Nov 2020
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
Read More
10 Nov 2020
Disposals of own shares
Read More
6 Nov 2020
UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020
Read More
31 Oct 2020
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients
Read More
Pagination
First page
Previous page
‹ Previous
…
Page
8
Page
9
Page
10
Page
11
Current page
12
Page
13
Page
14
Page
15
Page
16
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss